Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam
International Journal of Gynecology and Obstetrics, Volume 118, No. 2, Year 2012
Notification
URL copied to clipboard!
Description
Objective: To assess the potential advantages of combined mifepristone-misoprostol versus misoprostol-only for early medical abortion. Methods: A double-blind randomized placebo controlled study was conducted that enrolled 441 pregnant women (< 63 days since last menstrual period) at 2 hospitals in Tunisia and Vietnam. The mifepristone-misoprostol group (n = 220) received 200 mg of mifepristone on day 1 and 800 μg buccal misoprostol followed by placebo 3 hours later on day 2. The misoprostol-only group (n = 221) received placebo on day 1 and 1600 μg of misoprostol (2 doses of 800 μg, given 3 hours apart) on day 2. All medications were self-administered at home with follow-up 1 week later. The primary outcome was complete uterine evacuation without surgical intervention. Results: Successful uterine evacuation occurred for 78.0% (n = 170) of women with misoprostol only versus 92.9% (n = 195) of women with mifepristone-misoprostol (relative risk 0.84, 95% CI, 0.78-0.91; P < 0.001). Ongoing pregnancy occurred for 13.8% (n = 30) of women given misoprostol-only and 1.4% (n = 3) of women given mifepristone-misoprostol (relative risk 9.63, 95% CI 2.98-31.09; P < 0.001). Conclusion: Mifepristone plus misoprostol is significantly more effective than misoprostol-only for early medical abortion. Clinical trials.gov registration number: NCT00680394. © 2012 International Federation of Gynecology and Obstetrics.
Authors & Co-Authors
Blum, Jennifer
United States, New York
Gynuity Health Projects
Raghavan, Sheila
United States, New York
Gynuity Health Projects
Dabash, Rasha
United States, New York
Gynuity Health Projects
Ngoc, Nguyen Thi Nhu
Viet Nam, Ho Chi Minh City
Center for Research and Consultancy in Reproductive Health
Chélli, Héla
Tunisia, Tunis
Université de Tunis el Manar, Centre de Maternité et de Néonatologie
Hajri, Selma
Tunisia, Tunis
Université de Tunis el Manar, Centre de Maternité et de Néonatologie
Conkling, Kathryn
United States, New York
Gynuity Health Projects
Winikoff, Beverly
United States, New York
Gynuity Health Projects
Statistics
Citations: 42
Authors: 8
Affiliations: 3
Identifiers
Doi:
10.1016/j.ijgo.2012.03.039
ISSN:
00207292
e-ISSN:
18793479
Research Areas
Disability
Health System And Policy
Maternal And Child Health
Sexual And Reproductive Health
Study Design
Randomised Control Trial
Cohort Study
Study Locations
Tunisia
Participants Gender
Female